PYC.L
Physiomics Plc [PYC.L] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
PYC.L Stock Summary
Top 10 Correlated ETFs
PYC.L
Top 10 Correlated Stocks
PYC.L
In the News
PYC.L Financial details
Company Rating
-
Market Cap
1.63M
Income
-816.4K
Revenue
1.44M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
10
Optionable
No
Shortable
Yes
Earnings
05 Mar 2024
P/E
-3.25
Forward P/E
-
PEG
-0.16
P/S
3.82
P/B
2.91
P/C
-
P/FCF
-8.36
Quick Ratio
2.92
Current Ratio
4.63
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.01
EPS next Y
-
EPS next Q
-
EPS this Y
88.46%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
28.47%
Revenue last 5Y
-5.27%
Revenue Q/Q
44.21%
EPS Q/Q
-40%
-
-
-
-
SMA20
-2.33%
SMA50
-40%
SMA100
-38.24%
Inst Own
-
Inst Trans
-
ROA
-71%
ROE
-63%
ROC
-1.08%
Gross Margin
100%
Oper. Margin
-96%
Profit Margin
-80%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.9-3.288
52W High
-
52W Low
-
RSI
45.27
Rel Volume
14.96
Avg Volume
533.45K
Volume
7.98M
Perf Week
5.13%
Perf Month
-6.82%
Perf Quarter
-34.4%
Perf Half Y
-36.92%
-
-
-
-
Beta
1.78
-
-
Volatility
0.03%, 0.02%
Prev Close
-3.53%
Price
0.41
Change
-14.23%
Company Profile
- Volume Average 533.45K
- Market Capitalization 1.63M
- Employee 10
- CEO Dr. Peter Joseph Sargent
- Headquarters Oxford,GB
- IPO Date 2004-12-20
-
Website
https://www.physiomics.co.uk 
Physiomics Plc provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union. It offers modeling, simulation, and data analysis services covering various ranges of oncology research and development using its proprietary Virtual Tumour predictive software. The company also develops technology for use in the field of personalized medicine. Physiomics Plc was incorporated in 2001 and is based in Oxford, the United Kingdom.
